DeepMed Research

Amphotericin B

Generic Name: Amphotericin B

Brand Names: Abelcet, Ambisome, Amphotec, Fungizone

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₇₃NO_₁₇

CAS Number: 1397-89-3

Unique Ingredient Identifier: 7XU7A7DROE

Background: Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses.

Indication: Used to treat potentially life threatening fungal infections.

Associated Conditions: Coccidioidomycosis, Fungal Infections, Histoplasmosis, Invasive Aspergillosis, Invasive Fungal Infections, Leishmaniasis, Meningitis, Cryptococcal, Meningitis, Fungal, Mucocutaneous Leishmaniasis, Mycotic endophthalmitis, Penicillium marneffei infection, Visceral Leishmaniasis, Candidal cystitis, Disseminated Cryptococcosis, Fungal osteoarticular infections, Ocular aspergillosis, Refractory aspergillosis, Severe Coccidioidomycosis, Severe Cryptococcosis, Severe Fungal infection caused by Basidiobolus spp., Severe Fungal infection caused by Conidiobolus spp., Severe Fungal infection caused by sporotrichosis spp., Severe Histoplasmosis, Severe Mucocutaneous leishmaniasis, Severe North American blastomycosis, Severe Systemic candidiasis

Clinical Trials

Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis

Phase 3

Completed

Conditions: Acquired Immunodeficiency Syndrome
Aspergillosis
HIV Infections
Immunologic Deficiency Syndromes
Neutropenia

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 10

Registration Number: NCT00001646

Locations: 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States

Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis

Phase 2

Terminated

Conditions: Aspergillosis

Interventions: Drug: Micafungin
Drug: Liposomal Amphotericin B

First Posted Date: 2002-10-24

Last Posted Date: 2014-08-20

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 2

Registration Number: NCT00047827

A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis

Phase 3

Completed

Conditions: HIV Infections
Histoplasmosis
Blastomycosis

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Janssen, LP

Target Recruit Count: 60

Registration Number: NCT00002159

Locations: 🇺🇸
Community Hosp, Indianapolis, Indiana, United States
🇺🇸
LSU Med Ctr / Div of Pulmonary & Critical Care Med, Shreveport, Louisiana, United States
🇺🇸
Univ of Arkansas for Med Sciences, Little Rock, Arkansas, United States

and more 6 locations

A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success With Fluconazole

Phase 2

Completed

Conditions: Candidiasis, Oral
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 70

Registration Number: NCT00001065

Locations: 🇺🇸
The Ponce de Leon Ctr. CRS, Atlanta, Georgia, United States
🇺🇸
Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
🇺🇸
Weiss Memorial Hosp., Chicago, Illinois, United States

and more 29 locations

A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis

Not Applicable

Completed

Conditions: Meningitis, Cryptococcal
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 400

Registration Number: NCT00000639

Locations: 🇺🇸
Ucsf Aids Crs, San Francisco, California, United States
🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸
Northwestern University CRS, Chicago, Illinois, United States

and more 21 locations

Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS

Phase 3

Completed

Conditions: Meningitis, Cryptococcal
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2011-03-14

Lead Sponsor: Pfizer

Target Recruit Count: 330

Registration Number: NCT00001017

Locations: 🇺🇸
Beth Israel Deaconess - West Campus, Boston, Massachusetts, United States
🇺🇸
SUNY - Stony Brook, Stony Brook, New York, United States
🇺🇸
Duke Univ Med Ctr, Durham, North Carolina, United States

and more 25 locations

Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

Not Applicable

Completed

Conditions: Meningitis, Cryptococcal
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2011-03-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 120

Registration Number: NCT00000708

Locations: 🇺🇸
Univ of Miami School of Medicine, Miami, Florida, United States
🇺🇸
Julio Arroyo, West Columbia, South Carolina, United States
🇺🇸
Tulane Univ School of Medicine, New Orleans, Louisiana, United States

and more 3 locations

Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants

Phase 4

Completed

Conditions: Candidiasis

First Posted Date: 2001-08-31

Last Posted Date: 2010-08-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 500

Registration Number: NCT00001107

Locations: 🇺🇸
Mary Ellen Bradley, Birmingham, Alabama, United States

The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis

Phase 1

Completed

Conditions: Meningitis, Cryptococcal
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Alkermes, Inc.

Registration Number: NCT00002316

Locations: 🇺🇸
SUNY / Health Sciences Ctr at Stony Brook, Stony Brook, New York, United States
🇺🇸
Pennsylvania State Univ / Hershey Med Ctr, Hershey, Pennsylvania, United States
🇺🇸
Los Angeles County - USC Med Ctr, Los Angeles, California, United States

and more 8 locations

Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

Not Applicable

Completed

Conditions: Meningitis, Cryptococcal
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Pfizer

Registration Number: NCT00002075

Locations: 🇺🇸
Dr Robert Larsen, Los Angeles, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy